A Phase 4 interventional study of ADVAIR 100/50mcg and ADVAIR 250/50mcg in Asthma, sponsored by GlaxoSmithKline. Completed at 532 sites in 32 countries. Open to participants aged 4 Years to 11 Years. Per ClinicalTrials.gov, last updated 2018-08-06.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.
Among the 147 studies testing fluticasone in Asthma, this one is the 2nd largest by enrollment of the 146 interventional ones that give a count, is one of 8 that started in 2011, is one of 52 in phase 4, and was the 81st registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 4 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 8 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6,250 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 100 across the 146 interventional studies. Of the 130 that completed or were terminated, 68 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 147 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 2nd largest by enrollment of the 238 interventional ones that give a count, is one of 14 that started in 2011, is one of 53 in phase 4, and was the 135th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
2 of the studies testing fluticasone in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07664527University of Wisconsin, MadisonNovel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 147 studies testing fluticasone in Asthma, from their registry updates:
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, endotracheal intubations, and deaths) in children 4-11 years old taking inhaled fluticasone propionate/salmeterol combination is the same as those taking inhaled fluticasone propionate alone.
Progress of Enrollment, Updated Annually: This study has been completed and the final clinical study report was submitted to the FDA in May of 2016. This is the final update, as this study is complete.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
Drug: ADVAIR 100/50mcg
fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
Drug: ADVAIR 250/50mcg
fluticasone propionate (100) twice daily (AM and PM) for 6 months
Drug: FLOVENT 100mcg
fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
Drug: FLOVENT 250mcg
fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
Also known as: FSC 100/50
fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
Also known as: FSC 250/50
fluticasone propionate (100) twice daily (AM and PM) for 6 months
Also known as: FP 100
fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
Also known as: FP 250
Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death)
Composite endpoint was defined as clinically relevant endpoint that is constructed from combinations of other clinically relevant endpoints of serious asthma outcomes (i.e., asthma-related hospitalization, asthma-related endotracheal intubation, or asthma-related death). Hospitalization was defined as an inpatient stay or a \>=24-hour stay in an observation area in an emergency department or other equivalent facility. Time to first event in the composite endpoint of serious asthma-related outcomes over the 6-month study treatment period was analyzed using a Cox proportional hazards regression model. An estimate of absolute risk difference and its corresponding 95% confidence interval (CI) were also included. The Intent-to-Treat (ITT) Population included all participants randomized to study drug and who took study treatment.
Time frame: From Day 1 up to 6 months
Number of Participants With at Least One Asthma Exacerbation Over the 6-month Study Treatment Period
Number of participants with asthma exacerbation over the 6-month study treatment period are presented. Participants from mITT population with screening childhood asthma control test (C-ACT) scores of 20 or higher, one exacerbation in the previous year, and either low-dose inhaled corticosteroid (ICS) + one or more adjunctive therapy or medium-dose ICS monotherapy or medium-dose ICS and one or more adjunctive therapy as prior asthma therapy were included for this endpoint. Time to first exacerbation analyzed using a cox proportional hazards regression model. The number of asthma exacerbations were compared between treatments using a negative binomial regression model. The modified Intent-to-Treat (mITT) Population consisted of the ITT participants with a different data cut-off for supportive analyses of the primary composite safety endpoint.
Time frame: From Day 1 up to 6 months
Number of Participants Experiencing Asthma-related Deaths Over the 6-month Study Treatment Period.
Number of participants experiencing asthma-related death over the 6-month study treatment period are presented.
Time frame: From Day 1 up to 6 months
Number of Participants Experiencing Asthma-related Endotracheal Intubations Over the 6-month Study Treatment Period
Intubation is defined as endotracheal intubation with ventilation (mechanical or by hand). The number of participants experiencing asthma-related endotracheal intubations over the 6-month study treatment period are presented.
Time frame: From Day 1 up to 6 months
Number of Participants Experiencing Asthma-related Hospitalizations Over the 6-month Study Treatment Period
Hospitalization is defined as a \>=24-hour stay as an inpatient or in an observation ward. The number of participants experiencing asthma-related hospitalizations over the 6-month study treatment period are presented.
Time frame: From Day 1 up to 6 months
Number of Participants Withdrawn From Study Treatment Due to Asthma Exacerbation Over the 6-month Study Treatment Period
An exacerbation is defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days (up to 10 days) or a single depot corticosteroid injection. Number of participants experiencing at least one exacerbation from mITT population were included for this endpoint. The number of participants withdrawn from study treatment due to asthma exacerbation over the 6-month study treatment period are presented.
Time frame: From Day 1 up to 6 months
Percentage of Rescue-free Days Over the 6-month Study Treatment Period
Rescue-free days were days without use of rescue albuterol/salbutamol (other than pre-exercise treatment) over the 6-month study treatment period. The mean percentages of rescue-free days over the months 1-6 (defined as treatment days 2-182) are summarized. Number of participants over treatment days 2-182 from mITT Population were included for this endpoint.
Time frame: From Day 1 up to 6 months
Percentage of Asthma Control Days Over the 6-month Study Treatment Period
An asthma control day is one on which rescue albuterol/salbutamol use was recorded as 0, no night time awakenings were recorded, no asthma exacerbations were recorded, no work, school, or daycare days were missed by caregiver or participant due to asthma, coughing symptom score was \<=1 and wheezing symptom score was 0. The mean percentages of asthma control days over the months 1-6 (defined as treatment days 2-182) are summarized. Number of participants over treatment days 2-182 from mITT Population were included for this endpoint.
Time frame: From Day 1 up to 6 months
A total of 6250 participants were enrolled and randomized to study treatments; total 6208 participants took at least one dose of study drug.
| Milestone | Fluticasone Propionate/Salmeterol Combination (FSC) | Fluticasone Propionate (FP) |
|---|---|---|
| Started | 3107 | 3101 |
| Completed | 2724 | 2751 |
| Not completed | 383 | 350 |
| Withdrew: Withdrawal by subject | 245 | 226 |
| Withdrew: Adverse event | 24 | 23 |
| Withdrew: Asthma exacerbation | 34 | 35 |
| Withdrew: Lack of efficacy | 5 | 6 |
| Withdrew: Protocol violation | 68 | 53 |
| Withdrew: Lost to follow-up | 7 | 7 |
Composite endpoint was defined as clinically relevant endpoint that is constructed from combinations of other clinically relevant endpoints of serious asthma outcomes (i.e., asthma-related hospitalization, asthma-related endotracheal intubation, or asthma-related death). Hospitalization was defined as an inpatient stay or a \>=24-hour stay in an observation area in an emergency department or other equivalent facility. Time to first event in the composite endpoint of serious asthma-related outcomes over the 6-month study treatment period was analyzed using a Cox proportional hazards regression model. An estimate of absolute risk difference and its corresponding 95% confidence interval (CI) were also included. The Intent-to-Treat (ITT) Population included all participants randomized to study drug and who took study treatment.
| Participants | FSC DPI | FP DPI |
|---|---|---|
| Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death) | 27 | 21 |
Number of participants with asthma exacerbation over the 6-month study treatment period are presented. Participants from mITT population with screening childhood asthma control test (C-ACT) scores of 20 or higher, one exacerbation in the previous year, and either low-dose inhaled corticosteroid (ICS) + one or more adjunctive therapy or medium-dose ICS monotherapy or medium-dose ICS and one or more adjunctive therapy as prior asthma therapy were included for this endpoint. Time to first exacerbation analyzed using a cox proportional hazards regression model. The number of asthma exacerbations were compared between treatments using a negative binomial regression model. The modified Intent-to-Treat (mITT) Population consisted of the ITT participants with a different data cut-off for supportive analyses of the primary composite safety endpoint.
| Participants | FSC DPI | FP DPI |
|---|---|---|
| Number of Participants With at Least One Asthma Exacerbation Over the 6-month Study Treatment Period | 265 | 309 |
Number of participants experiencing asthma-related death over the 6-month study treatment period are presented.
| Participants | FSC DPI | FP DPI |
|---|---|---|
| Number of Participants Experiencing Asthma-related Deaths Over the 6-month Study Treatment Period. | 0 | 0 |
Intubation is defined as endotracheal intubation with ventilation (mechanical or by hand). The number of participants experiencing asthma-related endotracheal intubations over the 6-month study treatment period are presented.
| Participants | FSC DPI | FP DPI |
|---|---|---|
| Number of Participants Experiencing Asthma-related Endotracheal Intubations Over the 6-month Study Treatment Period | 0 | 0 |
Hospitalization is defined as a \>=24-hour stay as an inpatient or in an observation ward. The number of participants experiencing asthma-related hospitalizations over the 6-month study treatment period are presented.
| Participants | FSC DPI | FP DPI |
|---|---|---|
| Number of Participants Experiencing Asthma-related Hospitalizations Over the 6-month Study Treatment Period | 27 | 21 |
An exacerbation is defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days (up to 10 days) or a single depot corticosteroid injection. Number of participants experiencing at least one exacerbation from mITT population were included for this endpoint. The number of participants withdrawn from study treatment due to asthma exacerbation over the 6-month study treatment period are presented.
| Participants | FSC DPI | FP DPI |
|---|---|---|
| Number of Participants Withdrawn From Study Treatment Due to Asthma Exacerbation Over the 6-month Study Treatment Period | 33 | 35 |
Rescue-free days were days without use of rescue albuterol/salbutamol (other than pre-exercise treatment) over the 6-month study treatment period. The mean percentages of rescue-free days over the months 1-6 (defined as treatment days 2-182) are summarized. Number of participants over treatment days 2-182 from mITT Population were included for this endpoint.
| Percentage of rescue-free days | FSC DPI | FP DPI |
|---|---|---|
| Percentage of Rescue-free Days Over the 6-month Study Treatment Period | 83.0 ± 0.50 | 81.9 ± 0.52 |
An asthma control day is one on which rescue albuterol/salbutamol use was recorded as 0, no night time awakenings were recorded, no asthma exacerbations were recorded, no work, school, or daycare days were missed by caregiver or participant due to asthma, coughing symptom score was \<=1 and wheezing symptom score was 0. The mean percentages of asthma control days over the months 1-6 (defined as treatment days 2-182) are summarized. Number of participants over treatment days 2-182 from mITT Population were included for this endpoint.
| Percentage of asthma control days | FSC DPI | FP DPI |
|---|---|---|
| Percentage of Asthma Control Days Over the 6-month Study Treatment Period | 74.8 ± 0.57 | 73.4 ± 0.58 |
Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until follow-up (up to 6 months).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FSC DPI | — | 56/3,107 (1.8%) | 31/3,107 (1%) |
| FP DPI | — | 54/3,101 (1.7%) | 39/3,101 (1.3%) |
| Event | FSC DPI | FP DPI |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 23/3107 | 13/3101 |
| PneumoniaInfections and infestations | 11/3107 | 8/3101 |
| BronchitisInfections and infestations | 3/3107 | 2/3101 |
| Urinary tract infectionInfections and infestations | 1/3107 | 2/3101 |
| GastroenteritisInfections and infestations | 0/3107 | 2/3101 |
| TonsillitisInfections and infestations | 0/3107 | 2/3101 |
| ConcussionInjury, poisoning and procedural complications | 1/3107 | 2/3101 |
| Abdominal painGastrointestinal disorders | 0/3107 | 2/3101 |
| AppendicitisInfections and infestations | 1/3107 | 1/3101 |
| Lower respiratory tract infectionInfections and infestations | 1/3107 | 1/3101 |
| Event | FSC DPI | FP DPI |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 15/3107 | 23/3101 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/3107 | 2/3101 |
| HeadacheNervous system disorders | 2/3107 | 2/3101 |
| Upper respiratory tract infectionInfections and infestations | 2/3107 | 0/3101 |
| TremorNervous system disorders | 2/3107 | 0/3101 |
| InsomniaPsychiatric disorders | 2/3107 | 0/3101 |
| WheezingRespiratory, thoracic and mediastinal disorders | 1/3107 | 1/3101 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/3107 | 1/3101 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/3107 | 1/3101 |
| Pharyngeal inflammationRespiratory, thoracic and mediastinal disorders | 0/3107 | 1/3101 |
| Age, Continuous(Years) | FSC DPI | FP DPI | Total |
|---|---|---|---|
| Mean | 7.6 ± 2.21 | 7.6 ± 2.20 | 7.6 ± 2.20 |
| Sex: Female, Male(Participants) | FSC DPI | FP DPI | Total |
|---|---|---|---|
| Female | 1187 | 1227 | 2414 |
| Male | 1920 | 1874 | 3794 |
| Race/Ethnicity, Customized(Participants) | FSC DPI | FP DPI | Total |
|---|---|---|---|
| African American / African Heritage | 539 | 511 | 1050 |
| American Indian or Alaskan Native | 144 | 118 | 262 |
| Asian - Central / South Asian Heritage | 30 | 37 | 67 |
| Asian - East Asian Heritage | 96 | 112 | 208 |
| Japanese Heritage | 1 | 0 | 1 |
| Asian - South East Asian Heritage | 122 | 108 | 230 |
| Native Hawaiian or Other Pacific Islander | 5 | 1 | 6 |
| White - Arabic / North African Heritage | 13 | 15 | 28 |
| White - White / Caucasian / European Heritage | 1985 | 2017 | 4002 |
| Mixed Race | 167 | 180 | 347 |
| Missing | 5 | 2 | 7 |
Showing the first 100 of 532 sites across 32 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Nov 2011, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone